The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases

Textbook of Bone Metastases

Volumn , Issue , 2006, Pages 51-62

  Coleman, Robert E ^a   Dunstan, Colin R ^b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

Bone resorption and vascularisation; Inhibition of RANKL signalling; Lytic bone metastases; OPG RANKL RANK axis; RANK ligand and osteoprotegerin; RANKL AND OPG; RANKL expression; RANKL RANK signalling; Regulation of bone resorption

Indexed keywords

EID: 84889487403     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470011610.ch4     Document Type: Chapter

References (73)

1. Rodan GA, Martin TJ. Role of osteoblasts in hormonalcontrol of bone resorption-a hypothesis. CalcifiedTissue Int 1981; 33: 349-51.
2. Chambers TJ. The regulation of osteoclastic developmentand function. CIBA Foundation Symposium 1988; 136: 92-107.
3. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin:a novel secreted protein involved in the regulationof bone density. Cell 1997; 89: 309-19.
4. Tsuda E, Goto M, Mochizuki S-I et al. Isolation of anovel cytokine from human fibroblasts that specificallyinhibits bone osteoclastogenesis. Biochem Biophys ResCommun 1997; 234: 137-42.
5. Yamaguchi K, Kinosaki M, Goto M et al. Characterizationof the structural domains of human osteoclastogenesisinhibitory factor. J Biol Chem 1998; 273: 5117-23.
6. Yasuda H, Shima N, Nakagawa N et al. Osteoclastdifferentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical toTRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597-602.
7. Lacey DL, Timms E, Tan H-L et al. Osteoprotegerinligand is a cytokine that regulates osteoclast differentiationand activation. Cell 1998; 93: 165-76.
8. Wong BR, Josien R, Lee SY et al. TRANCE (tumornecrosis factor (TNF)-related activation-induced cytokine),a new TNF family member predominantlyexpressed in T cells, is a dendritic cell-specific survivalfactor. J Exp Med 1997; 186: 2075-80.
9. Anderson DM, Maraskovsky E, Billingsley WL et al. Ahomologue of the TNF receptor and its ligand enhance Tcell growth and dendritic cell function. Nature 1997; 390:175-9.
10. Nakagawa N, Kinosaki M, Yamaguchi K et al. RANK isthe essential signaling receptor for osteoclast differentiationfactor in osteoclastogenesis. Biochem Biophys ResCommun 1998; 253: 395-400.
11. Hsu H, Lacey DL, Dunstan CR et al. The TNFR-relatedprotein RANK is the osteoclast differentiation andactivation receptor for osteoprotegerin ligand. Proc NatlAcad Sci USA 1999; 96: 3540-5.
12. Hakeda H, Kobayashi Y, Yamaguchi K et al. Osteoclastogenesisinhibitory factor (OCIF) directly inhibits boneresorbingactivity of isolated mature osteoclasts. BiochemBiophys Res Commun 1998; 251: 796-801.
13. Burgess TL, Qian Y-X, Kaufman S et al. The ligand forosteoprotegerin (RANKL) directly activates matureosteoclasts. J Cell Biol 1999; 145: 527-38.
14. Lum L, Wong BR, Josien R et al. Evidence for a role of atumor necrosis factor-a (TNF-a)-converting enzyme-likeprotease in shedding of TRANCE a TNF family memberinvolved in osteoclastogenesis and dendritic cell survival.J Biol Chem 1999; 274: 18613-18.
15. Fuller K, Wong B, Fox S et al. TRANCE is necessaryand sufficient for osteoblast-mediated activation of boneresorption in osteoclasts. J Exp Med 1998; 188: 997-1001.
16. Jimi E, Akiyama S, Tsurukai T et al. Osteoclastdifferentiation factor acts as a multifunctional regulatorin murine osteoclast differentiation and function. JImmunology 1999; 163: 434-42.
17. Lacey DL, Tan HL, Lu J et al. Osteoprotegerin ligandmodulates murine osteoclast survival in vitro and in vivo.Am J Pathol 2000; 157: 435-48.
18. Horwood NJ, Elliott J, Martin TJ, Gillespie MT.Osteotropic agents regulate the expression of osteoclastdifferentiation factor and osteoprotegerin in osteoblasticstromal cells. Endocrinology 1998; 139: 4743-6.
19. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerindeficientmice develop early onset osteoporosis andarterial calcification. Genes Dev 1998; 12: 1260-8.
20. Mizuno A, Amizuka N, Irie K et al. Severe osteoporosisin mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247: 610-15.
21. Kong Y-Y, Yoshida H, Sarosi I et al. OPGL is a keyregulator or osteoclastogenesis, lymphocyte developmentand lymph-node organogenesis. Nature 1999; 397: 315-23.
22. Dunstan CR. Osteoprotegerin and osteoprotegerin ligandmediate the local regulation of bone resorption.Endocrinologist 2000; 10: 18-21.
23. Hofbauer LC, Khosla S, Dunstan CR et al. The roles ofosteoprotegerin and osteoprotegerin ligand in the paracrineregulation of bone resorption. J Bone Mineral Res2000; 15: 2-12.
24. Hofbauer LC, Khosla S, Dunstan CR et al. Estrogenstimulates gene expression and protein production ofosteoprotegerin in human osteoblastic cells. Endocrinology1999; 140: 4367-70.
25. Morony S, Capparelli C, Lee R et al. A chimeric form ofosteoprotegerin inhibits hypercalcemia and boneresorption induced by IL-1b, TNFa, PTH, PTHrp, and1,25-dihydroxyvitamin D3. J Bone Min Res 1999; 14:1478-85.
26. Yamamoto M, Murakami T, Nishikawa M et al.Hypocalcemic effect of osteoclastogenesis inhibitoryfactor/osteoprotegerin in the thyroparathyroidectomizedrat. Endocrinology 1998; 139: 4012-15.
27. Kong YY, Feige U, Sarosi I et al. Activated T cellsregulate bone loss and joint destruction in adjuvantarthritis through osteoprotegerin ligand. Nature 1999;402: 304-9.
28. Matsuzaki K, Udagawa N, Takahashi N et al. Osteoclastdifferentiation factor (ODF) induces osteoclast-like cellformation in human peripheral blood mononuclearcell cultures. Biochem Biophys Res Commun 1998; 246:199-204.
29. Shalhoub V, Faust J, Boyle WJ et al. Osteoprotegerinand osteoprotegerin ligand effects on osteoclast formationfrom human peripheral blood mononuclear cellprecursors. J Cell Biochem 1999; 72: 251-61.
30. Li J, Sarosi I, Yan XQ et al. RANK is the intrinsichematopoietic cell surface receptor that controls osteoclastogenesisand regulation of bone mass and calciummetabolism. Proc Natl Acad Sci USA 2000; 97: 1566-71.
31. Yano K, Tsuda E, Washida N et al. Immunologicalcharacterization of circulating osteoprotegerin/osteoclastogenesisinhibitory factor: increased serum concentrationsin postmenopausal women with osteoporosis. JBone Min Res 1999; 14: 518-27.
32. Arrighi HM, Hsieh A, Wong V et al. Osteoprotegerinserum levels in healthy volunteers. Bone 1998; 23: S298.
33. Bekker PJ, Holloway D, Nakanishi A et al. The effect ofa single dose of osteoprotegerin in postmenopausalwomen. J Bone Min Res 2001; 16: 348-60.
34. Hughes AE, Ralston SH, Marken J et al. Mutations inTNFRSF11A, affecting the signal peptide of RANK,cause familial expansile osteolysis. Nature Genet 2000;24: 45-8.
35. Fata JE, Kong Y-Y, Li J et al. The osteoclastdifferentiation factor osteoprotegerin-ligand is essentialfor mammary gland development. Cell 2000; 103: 41-50.
36. Emery JG, McDonnell P, Burke MB et al. Osteoprotegerinis a receptor for the cyotoxic ligand TRAIL. J BiolChem 1998; 273: 14363-7.
37. Tomoyasu A, Goto M, Fujise N et al. Characterizationof monomeric and homodimeric forms of osteoclastogenesisinhibitory factor. Biochem Biophys Res Commun1998; 245: 382-7.
38. Brown JM, Corey E, Lee ZD et al. Osteoprotegerin andRANK ligand expression in prostate cancer. Urology2001; 57: 611-16.
39. Seidel C, Hjertner O, Abilgaard N et al. Serumosteoprotegerin levels are reduced in patients withmultiple myeloma with lytic bone disease. Blood 2001;998: 2269-71.
40. Giuliani N, Bataille R, Mancini C et al. Myeloma cellsinduce imbalance in the osteoprotegerin/osteoprotegerinligand system in the human bone marrow environment.Blood 2001; 98: 3527-33.
41. Borset M, Standal T, Hjertner O et al. Binding,internalization and degradation of osteoprotegerin inhuman myeloma cells (abstr). Blood 2001; 98: 636a.
42. Boyde A, Maconnachie E, Reid SA et al. Scanningelectron microscopy in bone pathology: review ofmethods. Potential and applications. Scanning Electron Microsc 1986; IV: 1537-44.
43. Taube T, Elomaa I, Blomqvist C et al. Histomorphometricevidence for osteoclast-mediated bone resorptionin metastatic breast cancer. Bone 1994; 15: 161-6.
44. Sasaki A, Boyce BF, Story B et al. Bisphosphonaterisedronate reduces metastatic human breast cancerburden in bone in nude mice. Cancer Res 1995; 55:3551-7.
45. Sanchez-Sweatman OH, Lee J, Orr FW, Singh G. Directosteolysis induced by metastatic murine melanoma cells:role of matrix metalloproteinases. Eur J Cancer 1997; 33:918-25.
46. Littlewood-Evans AJ, Bilbe G, Bowler WB et al. Theosteoclast-associated protease cathepsin K is expressed inhuman breast carcinoma. Cancer Res 1997; 57: 5386-90.
47. Mancino AT, Klimberg VS, Yamamoto M et al. Breastcancer increases osteoclastogenesis by secreting M-CSFand upregulating RANKL in stromal cells. J Surg Res2001; 100: 18-24.
48. Chikatsu N, Takeuchi Y, Tamura Y et al. Interactionsbetween cancer and bone marrow cells induce osteoclastdifferentiation factor expression and osteoclast-like cellformation in vitro. Biochem Biophys Res Commun 2000;267: 632-7.
49. Nagai M, Kyakumoto S, Sata N. Cancer cells responsibleof humoral hypercalcemia express mRNA encoding asecreted form of ODF/TRANCE that induces osteoclastformation. Biochem Biophys Res Commun 2000; 269:532-6.
50. Nakchbandi IA, Weir EE, Insogna KL et al. Parathyroidhormone-related protein induces sponstaneous osteoclastsformation via a paracrine cascade. Proc Natl AcadSci USA 2000; 97: 7296-300.
51. Han J-J, Choi SJ, Kurihara N et al. Macrophageinflammatory protein-1 is an osteoclastogenic factor inmyeloma that is independent of receptor activator ofnuclear factor B ligand. Blood 2001; 97: 3349-53.
52. Pearse RN, Sordillo EM, Yaccoby S et al. Multiplemyeloma disrupts the TRANCE/osteoprotegerin cytokineaxis to trigger bone destruction and promote tumorprogression. Proc Natl Acad Sci USA 2001; 98: 11581-6.
53. Michigami T, Shimizu N, Williams PJ et al. Cell-cellcontact between marrow stromal cells and myeloma cellsvia VCAM-1 and a(4)b(1)-integrin enhances production ofosteoclast stimulating activity. Blood 1998; 96: 1953-60.
54. Akatsu T, Murakami T, Onon K et al. Osteoclastogenesisinhibitory factor exhibits hypocalcemic effects in normalmice and in hypercalcemic nude mice carrying tumorsassociated with humoral hypercalcemia of malignancy.Bone 1998; 23: 495-8.
55. Capparelli C, Kostenuik PJ, Morony S et al. Osteoprotegerinprevents and reverses hypercalcemia in a murinemodel of humoral hypercalcemia of malignancy. CancerRes 2000; 60: 783-7.
56. Morony S, Capparelli C, Sarosi I, Lacey DL, DunstanCR, Kostenuik PJ. Osteoprotegerin (OPG) inhibitsosteolysis and decreases skeletal tumor burden insyngeneic and nude mouse models of experimental bonemetastasis. Cancer Res 2001; 61: 4432-6.
57. Oyajobi BO, Anderson DM, Traianedes K et al.Therapeutic efficacy of a soluble receptor activator ofnuclear factor B-IgG Fc fusion protein in suppressingbone resorption and hypercalcemia in a model ofhumoral hypercalcemia of malignancy. Cancer Res2001; 61: 2572-8.
58. Croucher PI, Shipman CM, Lippitt J et al. Osteoprotegerininhibits the development of osteolytic bone diseasein multiple myeloma. Blood 2001; 98: 3534-40.
59. Honore P, Luger NM, Sabino MAC et al. Osteoprotegerinblocks bone cancer-induced skeletal destruction,skeletal pain and pain-related neurochemical reorganizationof the spinal cord. Nature Med 2000; 6: 521-8.
60. Wani MR, Fuller K, Kim NS et al. Prostaglandin E2cooperates with TRANCE in osteoclast induction. J BiolChem 1997; 272: 25190-4.
61. Body J-J, Lipton A, Coleman RE et al. An OPGconstruct decreases bone resorption profoundly in breastcancer bone metastasis. J Bone Min Metab 2001;19(suppl): 51.
62. Greipp P, Facon T, Williams CD et al. A singlesubcutaneous dose of an osteoprotegerin (OPG) construct(AMGN-0007) causes a profound and sustaineddecrease of bone resorption comparable to standardintravenous bisphosphonate in patients with multiplemyeloma. Blood 2001; 98(11): 775a.
63. Guise TA. Molecular mechanisms of osteolytic bonemetastases. Cancer 2000; 88 (suppl): 2892-8.
64. Welch DR, Fabra A, Nakajima M. Transforming growthfactor stimulates mammary adenocarcinoma cellinvasion and metastasis. Proc Natl Acad Sci USA 1990;87: 7678-82.
65. Myoui A, Sasaki P, Williams P et al. Bone-derivedgrowth factors enhance breast cancer metastasis to bone.J Bone Min Res 1996; 11(suppl 1): S481 (abstr).
66. Yin JJ, Selander K, Rankin W et al. The effects oftransforming growth factor-b on breast cancer-mediatedosteolysis are mediated by parathyroid hormone-relatedprotein via the Smad signaling pathway. J Bone Min Res 1999; 14(suppl 1).
67. Diel IJ, Solomayer EF, Costa SD et al. Reduction in newmetastases in breast cancer with adjuvant clodronatetreatment. N Engl J Med 1998; 339: 356-63.
68. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvantclodronate treatment does not reduce the frequency ofskeletal metastases in node-positive breast cancerpatients: 5-year results of a randomized controlled study.J Clin Oncol 2001; 19: 10-17.
69. Clohisy DR, Ramnaraine ML, Scully S et al. Osteoprotegerininhibits tumor-induced osteoclastogenesis andbone tumor growth in osteopetrotic mice. J Orthop Res2000; 18: 967-76.
70. Zhang J, Dai J, Qi Y et al. Osteoprotegerin inhibitsprostate cancer-induced osteoclastogenesis and preventsprostate tumor growth in the bone. J Clin Invest 2001;107: 1235-44.
71. Wong BR, Josien R, Lee SY et al. The TRAF family ofsignal transducers mediates NF-kB activation by theTRANCE receptor. J Biol Chem 1998; 273: 28335-59.
72. Lomaga MA, Yeh WC, Sarosi I et al. TRAF6-deficientmice are osteopetrotic and defective in interleukin-1,interleukin-18, CD40 and LPS signaling. Genes Dev1999; 13: 1015-24.
73. Iotsova V, Caamano J, Loy J et al. Osteopetrosis in micelacking NF-kB1 and NF-kB2. Nature Med 1997; 3:1285-9.